Earlier studies suggest that semaglutide (sold as Ozempic, Wegovy, and Rybelsus) may cause more digestive issues, including diarrhea, than older GLP-1 medications like liraglutide (Saxenda and Victoza)
In a 3-month randomized controlled study of type 2 diabetes, it was found that the combination of liraglutide and sitagliptin had no effect on the composition of intestinal flora, had no effect on the alpha and beta diversity, but liraglutide resulted in an elevation of deoxycholic acid (DCA) levels, indicating potential modulation of bile acid metabolism (Smits et al., 2021)
The temporary program, which runs until the end of 2027, is the first opportunity for most older adults to get GLP-1s, short for glucagon-like peptide-1 receptor agonists, covered by insurance when used strictly for weight loss
This is particularly relevant for patients on insulin therapy experiencing significant improvements in glycaemic control